

PRODUCT INFORMATION

Clone ID	DMC270
Target	CD160
Synonyms	BY55; NK1; NK28
Host Species	Rabbit
Description	Biotinylated Anti-CD160 antibody(DMC270); IgG1 Chimeric mAb
Delivery	2-3 weeks
Uniprot ID	O95971
IgG type	Rabbit/Human Fc chimeric IgG1
Clonality	Monoclonal
Reactivity	Human
Applications	Flow Cyt
Recommended Dilutions	Flow Cyt 1:100
Purification	Purified from cell culture supernatant by affinity chromatography
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Storage & Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	CD160 is an 27 kDa glycoprotein which was initially identified with the monoclonal antibody BY55. Its expression is tightly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity. The cDNA sequence of CD160 predicts a cysteine-rich; glycosylphosphatidylinositol-anchored protein of 181 amino acids with a single Ig-like domain weakly homologous to KIR2DL4 molecule. CD160 is expressed at the cell surface as a tightly disulfide-linked multimer. RNA blot analysis revealed CD160 mRNAs of 1.5 and 1.6 kb whose expression was highly restricted to circulating NK and T cells; spleen and small intestine. Within NK cells CD160 is expressed by CD56dimCD16 cells whereas among circulating T cells its expression is mainly restricted to TCRgd bearing cells and to TCRab CD8brightCD95 CD56 CD28-CD27-cells. In tissues; CD160 is expressed on all intestinal intraepithelial lymphocytes. CD160 shows a broad specificity for binding to both classical and nonclassical MHC class I molecules.
Usage	Research use only
Conjugate	Biotinylated
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.



DIMABIO CONFIDENTIAL

